Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.64 USD
Change Today +0.005 / 0.19%
Volume 564.9K
ATNM On Other Exchanges
As of 3:58 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/14 - $8.12
52 Week Low
05/18/15 - $2.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products include Actimab-A, an antibody-drug construct, which includes monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct that comprises the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, and is used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its Iomab-B is in preparation for a Phase III multicenter clinical trial for bone marrow conditioning for HSCT in relapsed and refractory AML patients. The company was founded in 2000 and is based in New York, New York.

12 Employees
Last Reported Date: 03/16/15
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $442.0K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc. Announces Clinical Update on Actimab A at Upcoming 2015 ASCO Annual Meeting

Actinium Pharmaceuticals, Inc. announced the upcoming poster and abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, to be held in Chicago on May 29 - June 2. Data will be presented from the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients. Clinical data from the first three cohorts will be discussed. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi. The Company also recently announced that it began the fourth and last cohort (2.0 Ci/kg per dose) in the Phase I portion of this trial. //st Title: Phase I trial of a-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) &low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Actinium Pharmaceuticals, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 10:30 AM

Actinium Pharmaceuticals, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 10:30 AM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States.

Actinium Pharmaceuticals, Inc. Appoints Jeng-Dar Yang as Vice President of Pharmaceutical Development

Actinium Pharmaceuticals, Inc. announced the appointment of Jeng-Dar Yang, Ph.D. to the position of Vice President of Pharmaceutical Development effective May 4, 2015. Dr. Yang brings with him 23 years of biotechnology experience in increasingly senior roles. Dr. Yang joins Actinium Pharmaceuticals from Immunomedics Inc. where he was the Executive Director, Cell Culture Production.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $2.64 USD +0.005

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at